BioSpace News Archive

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) submitted by Janssen Biotech, Inc.

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing

Bayer announced today a series of actions it plans to implement following the denial of the motion to preliminarily approve the Roundup™ class settlement agreement, designed to address potential future litigation, by Judge Vince Chhabria of the U.S. District Court for the Northern District of California.

Scopus BioPharma Inc. announced it will be rescheduling the company’s 2021 Annual Meeting of Shareholders, which was previously scheduled for July 16, 2021.

SOC Telemed, Inc., the largest national provider of acute care telemedicine, announced the pricing of its previously announced underwritten public offering of 8,000,000 shares of its Class A Common Stock at a price to the public of $6.00 per share.

Colorado Biolabs, Inc. and MFB Fertility, Inc. are pleased to announce a strategic alliance granting MFB Fertility US distribution rights to Proferrin® Heme Iron Polypeptide, a unique form of iron, for future Proov® brand products.

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock and accompanying investor warrants to purchase up to 6,000,000 shares of common stock.

EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as the Chief Technology Officer of EpimAb.

Foresee Pharmaceuticals, announced that the U.S. Food and Drug Administration has approved the New Drug Application for CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer.

Turner Imaging Systems, a developer of advanced X-ray imaging systems, today announced the Company has received its CE Mark for its Smart-C ® Mini C-Arm portable fluoroscopy x-ray imaging device.